Moderna announces new combination vaccine candidate targeting COVID-19 and flu

224
39
Favorite

Moderna announces new combination vaccine candidate targeting COVID-19 and flu

seekingalpha2021-09-09

(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu. Moderna highlighted the strength of its pipeline and revised ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

224

Report

Comment（39）

Keez
·2021-09-14
Ok
Reply
Like
Report
壮志高飞
·2021-09-10
Cash cow imagine 50% of the world population vaccinated
Reply
1
Report
Fold Replies
- KDaDa:
  Wow!
  2021-09-14
  Reply
  Report
Lalalanana
·2021-09-10
Up up up
Reply
1
Report
koolgal
·2021-09-10
Moderna is in the money with 2 in 1 Covid-19 vaccine cum flu. Investors can expect bumper profits along the way. ?????
Reply
8
Report
PhilipGoh
·2021-09-10
Yes buy[開心]
Reply
1
Report
FT585
·2021-09-10
Nice
Reply
1
Report
A68
·2021-09-10
OK
Reply
2
Report
ahoon
·2021-09-10
Good
Reply
3
Report
MetalGuru
·2021-09-10
Reach for the stars
Reply
3
Report
sickeninglim
·2021-09-10
Wow....
Reply
5
Report
lewisleeks
·2021-09-10
Wow nice,don’t stop[Miser] [Miser] [Miser] [Miser]
Reply
6
Report
Fold Replies
- koolgal:
  ??
  2021-09-11
  Reply
  Report
来人
·2021-09-10
Nice
Reply
5
Report
LST3
·2021-09-10
Good
Reply
5
Report
Lamborghini1
·2021-09-10
Good
Reply
8
Report
Bryonie
·2021-09-10
Well
Reply
8
Report
Fold Replies
- SeC:
  ?
  2021-09-11
  Reply
  Report
Calvinkuah
·2021-09-09
Great!
Reply
6
Report
Fold Replies
- KH17:
  Yes
  2021-09-09
  Reply
  Report
LaiSB
·2021-09-09
Good job
Reply
4
Report
Fold Replies
- Hb_:
  w
  2021-09-09
  Reply
  Report
MetalGuru
·2021-09-09
rise higher
Reply
2
Report
Fold Replies
- MonKeyTgr:
  ok
  2021-09-09
  Reply
  Report
- LaiSB:
  Up up up
  2021-09-09
  Reply
  Report
xiaoming1
·2021-09-09
Okok
Reply
2
Report
Fold Replies
- CWL711:
  Okok
  2021-09-09
  Reply
  Report
Minhoshuting
·2021-09-09
Nice
Reply
4
Report
Fold Replies
- xiaoming1:
  Nice
  2021-09-09
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1169339361?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-09 22:21","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1169339361","market":"us","top_or_hot":-1,"title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","media":"seekingalpha","content":"<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","article_id":"1169339361","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","pubTimestamp":1631197303,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳宣布针对新冠肺炎和流感的新组合候选疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":886318498,"gmtCreate":1631550514214,"gmtModify":1676530574400,"author":{"id":"4089085863454690","authorId":"4089085863454690","name":"Keez","avatar":"https://static.itradeup.com/news/50ca1de8e0d9b1984d987c9a235af23a","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"authorIdStr":"4089085863454690","idStr":"4089085863454690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886318498","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":881097592,"gmtCreate":1631280469516,"gmtModify":1676530517364,"author":{"id":"3554819591940598","authorId":"3554819591940598","name":"壮志高飞","avatar":"https://static.tigerbbs.com/d49448839db6ec13a56ec95df9761db9","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3554819591940598","idStr":"3554819591940598"},"htmlText":"Cash cow imagine 50% of the world population vaccinated","listText":"Cash cow imagine 50% of the world population vaccinated","text":"Cash cow imagine 50% of the world population vaccinated","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881097592","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5856221,"gmtCreate":1631549536096,"gmtModify":1663233830725,"authorId":3586642856771590,"author":{"id":3586642856771590,"idStr":"3586642856771590","authorId":3586642856771590,"name":"KDaDa","avatar":"https://static.tigerbbs.com/bbf594380f656556b95e862fd6513d46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":881097592,"type":1,"supId":0,"prevId":0,"content":"Wow!","text":"Wow!","html":"Wow!"}],"langContent":"EN"},{"id":883491116,"gmtCreate":1631261670435,"gmtModify":1676530512073,"author":{"id":"3575357409343512","authorId":"3575357409343512","name":"Lalalanana","avatar":"https://static.tigerbbs.com/1dc07195419b4d0af32837fd05440883","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575357409343512","idStr":"3575357409343512"},"htmlText":"Up up up&nbsp;","listText":"Up up up&nbsp;","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883491116","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883282507,"gmtCreate":1631244428309,"gmtModify":1676530507477,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3559581955535845","idStr":"3559581955535845"},"htmlText":"Moderna is in the money with 2 in 1 Covid-19 vaccine cum flu.&nbsp; Investors can expect bumper profits along the way. ?????","listText":"Moderna is in the money with 2 in 1 Covid-19 vaccine cum flu.&nbsp; Investors can expect bumper profits along the way. ?????","text":"Moderna is in the money with 2 in 1 Covid-19 vaccine cum flu. Investors can expect bumper profits along the way. ?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883282507","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883641800,"gmtCreate":1631239769300,"gmtModify":1676530505641,"author":{"id":"3574730309796268","authorId":"3574730309796268","name":"PhilipGoh","avatar":"https://static.tigerbbs.com/d6085185a57dcb9a222e871338387428","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3574730309796268","idStr":"3574730309796268"},"htmlText":"Yes buy[開心]&nbsp;","listText":"Yes buy[開心]&nbsp;","text":"Yes buy[開心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883641800","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":883650603,"gmtCreate":1631239155602,"gmtModify":1676530505345,"author":{"id":"3562726241279787","authorId":"3562726241279787","name":"FT585","avatar":"https://static.tigerbbs.com/734b50619b12425294cb4715814bdedb","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3562726241279787","idStr":"3562726241279787"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883650603","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883614974,"gmtCreate":1631237628698,"gmtModify":1676530504463,"author":{"id":"3576813955258325","authorId":"3576813955258325","name":"A68","avatar":"https://static.tigerbbs.com/d209afa981c29a4dc34bd7c1c986fb4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576813955258325","idStr":"3576813955258325"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883614974","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883843049,"gmtCreate":1631234612381,"gmtModify":1676530502824,"author":{"id":"4087362605261610","authorId":"4087362605261610","name":"ahoon","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087362605261610","idStr":"4087362605261610"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883843049","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883142008,"gmtCreate":1631229986804,"gmtModify":1676530500294,"author":{"id":"3584964198158897","authorId":"3584964198158897","name":"MetalGuru","avatar":"https://static.tigerbbs.com/1f9af4319fe386d09474d76fe72e470a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3584964198158897","idStr":"3584964198158897"},"htmlText":"Reach for the stars&nbsp;","listText":"Reach for the stars&nbsp;","text":"Reach for the stars","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883142008","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883157891,"gmtCreate":1631229617913,"gmtModify":1676530500119,"author":{"id":"3575453671192179","authorId":"3575453671192179","name":"sickeninglim","avatar":"https://static.tigerbbs.com/0753a2906468fc16c39e5f831b2200d7","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3575453671192179","idStr":"3575453671192179"},"htmlText":"Wow....","listText":"Wow....","text":"Wow....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883157891","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883152933,"gmtCreate":1631229409122,"gmtModify":1676530500048,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"4089010444435920","idStr":"4089010444435920"},"htmlText":"Wow nice,don’t stop[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"Wow nice,don’t stop[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"Wow nice,don’t stop[Miser] [Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883152933","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5826150,"gmtCreate":1631322636482,"gmtModify":1663233702736,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.25","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":883152933,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":883162454,"gmtCreate":1631227952678,"gmtModify":1676530499525,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3575544575320394","idStr":"3575544575320394"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883162454","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883197135,"gmtCreate":1631223194427,"gmtModify":1676530498503,"author":{"id":"3576578158811365","authorId":"3576578158811365","name":"LST3","avatar":"https://static.tigerbbs.com/5ebefe56c7d81742050e1a8d5a94ef9a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576578158811365","idStr":"3576578158811365"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883197135","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883198682,"gmtCreate":1631222101746,"gmtModify":1676530498397,"author":{"id":"3578903100181699","authorId":"3578903100181699","name":"Lamborghini1","avatar":"https://static.tigerbbs.com/f8b24a649554234324e1e33be42fc25f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3578903100181699","idStr":"3578903100181699"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883198682","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883358238,"gmtCreate":1631206023924,"gmtModify":1676530497271,"author":{"id":"3586074983708406","authorId":"3586074983708406","name":"Bryonie","avatar":"https://static.tigerbbs.com/40e9091aa418c1a4602b3db85fa8cf56","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586074983708406","idStr":"3586074983708406"},"htmlText":"Well&nbsp;","listText":"Well&nbsp;","text":"Well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883358238","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5823527,"gmtCreate":1631302266773,"gmtModify":1663233689348,"authorId":3582371848241817,"author":{"id":3582371848241817,"idStr":"3582371848241817","authorId":3582371848241817,"name":"SeC","avatar":"https://static.tigerbbs.com/a226cf90d6854e9178341c90697ce373","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883358238,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":883313449,"gmtCreate":1631201299281,"gmtModify":1676530496116,"author":{"id":"3576598609551552","authorId":"3576598609551552","name":"Calvinkuah","avatar":"https://static.tigerbbs.com/0e3e03014308cd647eda35cc3c01a986","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3576598609551552","idStr":"3576598609551552"},"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883313449","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808982,"gmtCreate":1631201339054,"gmtModify":1634804178436,"authorId":3581725928308654,"author":{"id":3581725928308654,"idStr":"3581725928308654","authorId":3581725928308654,"name":"KH17","avatar":"https://community-static.tradeup.com/news/fca4709c9440c2051f34c45337436bca","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883313449,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":883335696,"gmtCreate":1631200903615,"gmtModify":1676530495926,"author":{"id":"3585312804980408","authorId":"3585312804980408","name":"LaiSB","avatar":"https://static.tigerbbs.com/02ab60e191d391b446c88630f4f1e822","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585312804980408","idStr":"3585312804980408"},"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883335696","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808950,"gmtCreate":1631201202670,"gmtModify":1663233627925,"authorId":3575084008680468,"author":{"id":3575084008680468,"idStr":"3575084008680468","authorId":3575084008680468,"name":"Hb_","avatar":"https://static.tigerbbs.com/2e6b4bec98a0dbb1567834e4f467227b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883335696,"type":1,"supId":0,"prevId":0,"content":"<u>w</u>","text":"<u>w</u>","html":"<u>w</u>"}],"langContent":"EN"},{"id":883392070,"gmtCreate":1631200089490,"gmtModify":1676530495700,"author":{"id":"3584964198158897","authorId":"3584964198158897","name":"MetalGuru","avatar":"https://static.tigerbbs.com/1f9af4319fe386d09474d76fe72e470a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3584964198158897","idStr":"3584964198158897"},"htmlText":"rise higher","listText":"rise higher","text":"rise higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883392070","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808749,"gmtCreate":1631200215204,"gmtModify":1663233626137,"authorId":3581997518772824,"author":{"id":3581997518772824,"idStr":"3581997518772824","authorId":3581997518772824,"name":"MonKeyTgr","avatar":"https://static.tigerbbs.com/4ab27682077288c911a0756e5ad330a1","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883392070,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":5808881,"gmtCreate":1631200888088,"gmtModify":1663233625358,"authorId":3585312804980408,"author":{"id":3585312804980408,"idStr":"3585312804980408","authorId":3585312804980408,"name":"LaiSB","avatar":"https://static.tigerbbs.com/02ab60e191d391b446c88630f4f1e822","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883392070,"type":1,"supId":0,"prevId":0,"content":"Up up up","text":"Up up up","html":"Up up up"}],"langContent":"EN"},{"id":883398348,"gmtCreate":1631199942984,"gmtModify":1676530495652,"author":{"id":"3583115173057099","authorId":"3583115173057099","name":"xiaoming1","avatar":"https://static.tigerbbs.com/ac37184a3e43827b0c0629f6fda7ea11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583115173057099","idStr":"3583115173057099"},"htmlText":"Okok","listText":"Okok","text":"Okok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883398348","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808884,"gmtCreate":1631200899143,"gmtModify":1663233625442,"authorId":3579262958727025,"author":{"id":3579262958727025,"idStr":"3579262958727025","authorId":3579262958727025,"name":"CWL711","avatar":"https://static.tigerbbs.com/982058e5cb33e9069dbb2ca28d3fc46e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883398348,"type":1,"supId":0,"prevId":0,"content":"Okok","text":"Okok","html":"Okok"}],"langContent":"EN"},{"id":883393998,"gmtCreate":1631199848514,"gmtModify":1676530495596,"author":{"id":"3577450970953718","authorId":"3577450970953718","name":"Minhoshuting","avatar":"https://static.tigerbbs.com/16ab92b2914bd064ccd8620ef1d430ff","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3577450970953718","idStr":"3577450970953718"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883393998","repostId":1169339361,"repostType":4,"repost":{"id":"1169339361","kind":"news","pubTimestamp":1631197303,"share":"https://ttm.financial/m/news/1169339361?lang=&edition=fundamental","pubTime":"2021-09-09 22:21","market":"us","language":"en","title":"Moderna announces new combination vaccine candidate targeting COVID-19 and flu","url":"https://stock-news.laohu8.com/highlight/detail?id=1169339361","media":"seekingalpha","summary":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine c","content":"<p>(Sept 9)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> jumped over 5% in early trading,&nbsp;after&nbsp;it announces new combination vaccine candidate targeting COVID-19 and flu.</p>\n<p><img src=\"https://static.tigerbbs.com/7eb113e06f2c08fc7e2b8910f8df71f8\" tg-width=\"1154\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna&nbsp;highlighted the strength of its pipeline and revised the cash position ahead of its R&amp;D Day Scheduled for&nbsp;Thursday at 8.00 AM EST.</p>\n<p>Issuing an update on R&amp;D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.</p>\n<p>mRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.</p>\n<p>With 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.</p>\n<p>Updating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end&nbsp;of the previous quarter.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna announces new combination vaccine candidate targeting COVID-19 and flu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna announces new combination vaccine candidate targeting COVID-19 and flu\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised ...</p>\n\n<a href=\"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3738257-moderna-updates-on-cash-position-and-unveils-new-combined-vaccine-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1169339361","content_text":"(Sept 9) Moderna, Inc. jumped over 5% in early trading, after it announces new combination vaccine candidate targeting COVID-19 and flu.\n\nModerna highlighted the strength of its pipeline and revised the cash position ahead of its R&D Day Scheduled for Thursday at 8.00 AM EST.\nIssuing an update on R&D programs, the company said it added a new combination vaccine candidate to the pipeline named mRNA-1073, which combines its COVID-19 vaccine and flu vaccine candidate.\nmRNA-1073, for which Moderna (MRNA) owns worldwide commercial rights, encodes for COVID-19 spike protein and the Flu HA glycoproteins.\nWith 22 clinical studies currently underway, the company now boasts 37 programs in development across 34 development candidates.\nUpdating the liquidity level, the company announced its cash position at about $15B as of August 31, up from ~$12.2B at the end of the previous quarter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808683,"gmtCreate":1631199951038,"gmtModify":1663233627949,"authorId":3583115173057099,"author":{"id":3583115173057099,"idStr":"3583115173057099","authorId":3583115173057099,"name":"xiaoming1","avatar":"https://static.tigerbbs.com/ac37184a3e43827b0c0629f6fda7ea11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883393998,"type":1,"supId":0,"prevId":0,"content":"<u>Nice</u>","text":"<u>Nice</u>","html":"<u>Nice</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":224,"commentSize":39,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}